公开(公告)号：US20210142173A1

公开(公告)日：2021-05-13

申请号：US17096712

申请日：2020-11-12

Applicant: THE CLEVELAND CLINIC FOUNDATION

Inventor： Feixiong Cheng

IPC: G06N3/08 ,  G16H20/10 ,  G06K9/62 ,  G06K9/66 ,  G06N5/00 ,  G06N3/04

Abstract: A system to implement a deep learning network model is disclosed. The system includes machine-readable instructions and data that include a biomedical information library comprising information that includes a plurality of drugs, a plurality of biological targets, a plurality of diseases, and a plurality of adverse effects, a biomedical network system comprising a plurality of networks covering chemical, genomic, phenotypic, and cellular profiles, a score prioritizer to determine new targets for the plurality of drugs based on a concatenation of a low-dimensional vector representation for each drug vertex and each biological target vertex, and a model generator configured to generate a deep learning network model that defines a plurality of relationships between the drugs, the biological targets, and the adverse effects. The plurality of relationships defined by the deep learning network model predict drug target identification and drug repurposing.

公开(公告)号：US20240009299A1

公开(公告)日：2024-01-11

申请号：US18040531

申请日：2021-08-04

Applicant: The Cleveland Clinic Foundation

Inventor： Feixiong Cheng ,  William Martin

IPC: A61K39/215 ,  A61P31/14

CPC classification number: A61K39/215 ,  A61P31/14 ,  A61K2039/55516

Abstract: The present invention provides compositions comprising polypeptides comprising a plurality of epitopes from the spike glycoprotein of SARS-CoV-2, systems, and methods of using thereof for the treatment of viral infections (e.g., coronavirus disease 2019 (COVID-19)).

公开(公告)号：US20230233489A1

公开(公告)日：2023-07-27

申请号：US18001832

申请日：2021-06-18

Applicant: THE CLEVELAND CLINIC FOUNDATION

Inventor： Feixiong Cheng ,  Reena Mehra ,  Sujata Rao ,  Yadi Zhou ,  Yuan Hou

IPC: A61K31/138 ,  A61K31/4045 ,  A61P31/14 ,  A61K9/00

CPC classification number: A61K31/138 ,  A61K31/4045 ,  A61P31/14 ,  A61K9/0053

Abstract: The present invention provides methods, compositions, combinations, and kits for treating a subject with a viral infection (e.g., COVID-19) by administering or providing an estrogen receptor modulator and an anti-inflammatory agent or by administering or providing an anti-inflammatory agent (e.g., melatonin) to the subject.